VPC
ONC

Vestal Point Capital’s BeOne Medicines Ltd ONC Stock Holding History

Vestal Point Capital’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-350,000
Closed -$49.9M – 85
2024
Q2 		$49.9M Buy
350,000
+25,000
+8% +$3.85M 3.72% 7
2024
Q1 		$50.8M Buy
+325,000
New +$52.3M 4.2% 8

Other funds holding ONC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vestal Point Capital's ONC Position: Q3 2024 in Review

Vestal Point Capital sold out of BeOne Medicines Ltd (ONC) in Q3 2024, closing a stake of 350,000 shares — an estimated $49.9M sold.

Vestal Point Capital first reported a position in ONC in Q1 2024 and held it in 2 quarters. The position peaked at $50.8M in Q1 2024. 228 funds tracked by Wall St. Rank hold ONC as of Q3 2024.

  • Vestal Point Capital reported no remaining BeOne Medicines Ltd position as of Q3 2024 after selling out during the quarter.
  • Vestal Point Capital sold 350,000 BeOne Medicines Ltd shares in Q3 2024, an estimated $49.9M.
  • Vestal Point Capital first reported a position in BeOne Medicines Ltd in Q1 2024 and held it in 2 quarters.
  • Vestal Point Capital's BeOne Medicines Ltd position peaked at $50.8M in Q1 2024.
  • 228 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q3 2024.

Based on Vestal Point Capital's 13F filing for Q3 2024, filed 14 Nov 2024.